Bone-marrow derived neurogenic cells and uses thereof

• US 20080138319A1
• Filed: 10/19/2007
• Published: 06/12/2008
• Est. Priority Date: 04/20/2005
• Status: Abandoned Application

• Current Assignee: University of Florida Research Foundation, Incorporated (State University System of Florida)
• Original Assignee: University of Florida (State University System of Florida)
• Inventors: Deng, Jie, Petersen, Bryon, Laywell, Eric D., Steindler, Dennis A.
• Application Number:
  US11/975,683
• Publication Number:
  US 20080138319A1
• Time in Patent Office: Days
• US Class Current: 424/93.2
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: C12N 2501/01 Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/13 Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
• CPC Class Codes: C12N 2501/235 Leukemia inhibitory factor [LIF]
• CPC Class Codes: C12N 2506/1353 from bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0619 Neurons
• CPC Class Codes: C12N 5/0622 Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells

Abstract

Disclosed are cellular compositions, grafts and pharmaceutical products made from bone marrow (BM) cells useful for a wide array of cell-based therapies for diseases and disorders of the nervous system. Transgenic cells in accord with the invention express therapeutic or reporter genes encoded in viral vectors. The cells are capable of extensive expansion in vitro and can generate neurons and glial cells both in culture and in vivo. Upon administration to a nervous system tissue or site in a host subject, the cells can migrate to appropriate target sites and can assimilate therein, differentiating into both neurons and astrocytes without evidence of fusion with endogenous cells of the host nervous tissue. The cells can express an array of therapeutic gene products suitable for treatment of nervous system disorders. Particularly preferred for neurodegenerative disease applications are transgenic BM-derived neurogenic cells expressing neurotrophic factors.

Claims

4. The neurogenic cell of claim 1-3, further comprising an expression vector comprising a nucleic acid sequence encoding a therapeutic or reporter gene.

5. An isolated population of neurogenic cells derived from bone marrow comprising cells capable of differentiating into a neuron or glial cell in vitro or when administered to a host subject.

6. The neurogenic cell population of claim 5, comprising the following marker expression profile in vitro:

undetectable or low levels of at least one of CD34, CD45, and CD11b;

detectable levels of at least one of CD105 and CD109;

undetectable or low levels of c-kit and detectable levels of sca-1; and

detectable or high levels of at least one of nestin, β

-III tubulin, and NFM, as determined by standard marker detection assay.

7. The neurogenic cell population of claim 5, further expressing detectable or high levels of at least one glial cell marker.

8. The neurogenic cell population of claim 5-7, further comprising an expression vector comprising a nucleic acid sequence encoding a therapeutic or reporter gene.

14. A method for delivering a bone-marrow derived neurogenic cell to a neural tissue of a host subject, comprising:

(a) culturing a population of bone marrow-derived cells under conditions to obtain an isolated neurogenic cell from the cell population;

(b) expanding said neurogenic cell in vitro, to obtain a cell population or graft enriched in bone marrow-derived neurogenic cells; and

(c) administering the cell population or graft of step (b) into the host subject, wherein a bone marrow-derived neurogenic cell or a progeny cell derived from said neurogenic cell populates at least one neural tissue of the subject.

1. An isolated neurogenic cell derived from bone marrow capable of differentiating into a neuron or glial cell in vitro or when administered to a host subject.

2. The neurogenic cell of claim 1, comprising the following marker expression profile in vitro:

undetectable or low levels of at least one of CD34, CD45, and CD11b;

detectable levels of at least one of CD105 and CD109;

undetectable or low levels of c-kit and detectable levels of sca-1; and

detectable or high levels of at least one of nestin, β

-III tubulin, and NFM, as determined by standard marker detection assay.

3. The neurogenic cell of claim 2, further expressing detectable or high levels of at least one glial cell marker.

9. A graft comprising at least one of the isolated neurogenic cells of claims 1-8.

10. A pharmaceutical product for preventing, treating or reducing the severity of a disorder of the nervous system, the product comprising at least one of the following components:

the isolated neurogenic cells of claims 1-8, the graft of claim 9, and optionally directions for preparing, maintaining and/or administering the cells or graft.

11. The pharmaceutical product of claim 10, wherein the neurogenic cell is a transgenic cell transduced with an expression vector comprising a nucleic acid sequence encoding a therapeutic gene.

12. The pharmaceutical product of claim 11, wherein the transgenic cell comprises a lentiviral vector.

13. The isolated neurogenic cell of claim 4, the neurogenic cell population of claim 5, the graft of claim 9, or the pharmaceutical product of claims 11-12, wherein the therapeutic gene is a neurotrophic factor selected from the group consisting of GDNF, BDNF, NGF, bFGF, and EGF.

15. The method of claim 14, wherein the population or graft of bone marrow-derived cells of step (a) is obtained from the host subject.

16. The method of claim 14, wherein the cell population is administered to a neural tissue of a host subject.

17. The method of claim 16, wherein the cell population or graft is administered to the brain.

18. The method of claim 16, wherein the cell population is administered to the spinal cord.

19. The method of claim 16, wherein the cell population is administered to a component of the peripheral nervous system.

22. A method for preventing, treating or reducing the severity of a disorder of the nervous system, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of the isolated neurogenic cells of any one of claims 1-13.

23. The method of claim 22, wherein the disorder of the nervous system is selected from the group consisting of Parkinson'"'"'s disease, Alzheimer'"'"'s disease, multiple sclerosis, Lewy body disease, amyotrophic lateral sclerosis, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, spinal cord injury, stroke, and paralysis.

17-1. The method of claim 14, wherein the administered neurogenic cell populates the brain of the subject.

18-2. The method of claim 14, wherein the administered neurogenic cell populates the spinal cord of the subject.

19-3. The method of claim 14, wherein the administered neurogenic cell populates a component of the peripheral nervous system of the subject.

20. The method of claim 14, wherein the neurogenic cell of step (b) comprises the following marker expression profile in vitro:

undetectable or low levels of at least one of CD34, CD45, and CD11b;

detectable levels of at least one of CD105 and CD109;

undetectable or low levels of c-kit and detectable levels of sca-1; and

detectable or high levels of at least one of nestin, β

-III tubulin, and NFM,

and optionally, detectable levels of GFAP, as determined by standard marker detection assay.

21. The method of claim 20, wherein the therapeutic gene is a neurotrophic factor.

20-4. A method for expressing a therapeutic or reporter gene in a neural tissue, comprising:

(a) culturing a population of bone marrow-derived cells under conditions to obtain an isolated neurogenic cell from the cell population;

(b) expanding said neurogenic cell in vitro, to obtain a cell population or graft enriched in bone marrow-derived neurogenic cells;

(c) contacting the neurogenic cell of step (a) or (b) with an expression vector comprising a therapeutic or reporter gene, to obtain transgenic bone marrow-derived neurogenic cells transduced with said vector; and

(d) administering the cell population or graft of step (c) into the host subject, wherein a transgenic neurogenic cell or a progeny cell derived therefrom populates at least one neural tissue of the subject and expresses the therapeutic or reporter gene.